The FDA approves an antibody-drug conjugate that effectively treats a certain type of advanced breast cancer with fewer side effects than previous drugs.
Advertisement
The Scientist
Most Recent
Input lines are open for the National Institute of Substance Use and Addiction Disorders.
After a lightning-fast approval, the first medicine to treat an underlying cause of the disorder hits the market.
A list of this year’s newsworthy successes—and failures—in drug development
The pharmaceutical darling that has brought billions in revenue to Pfizer over the past 15 years will now share the shelves with its generic competitors.
Forensic labs in the United States should be better equipped to identify a new crop of recreational drug mimics.
Page 1 of 1
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
